Latest News

Camizestrant/Ribociclib Improves PFS and Responses in ER+/HER2– Breast Cancer
Camizestrant/Ribociclib Improves PFS and Responses in ER+/HER2– Breast Cancer

December 15th 2024

Patients with ER+/HER2– advanced breast cancer saw positive efficacy and safety data following treatment from the SERENA-1 trial.

ctDNA at Baseline Linked With Larger Tumor Size and Residual Cancer Burden
ctDNA at Baseline Linked With Larger Tumor Size and Residual Cancer Burden

December 14th 2024

Atezolizumab with Neoadjuvant Chemo Does Not Meet End Points in TNBC
Atezolizumab with Neoadjuvant Chemo Does Not Meet End Points in TNBC

December 13th 2024

Of 18 patients with BRCA-mutated ER+/HER2– breast cancer, 3 had a pathological complete response when treated with niraparib plus dostarlimab.
Niraparib/Dostarlimab Shows Promise in BRCA+ ER+/HER2– Breast Cancer

December 13th 2024